OR WAIT null SECS
WuXi STA has finalized its acquisition of Bristol Myers Squibb’s drug product manufacturing facility based in Couvet, Switzerland.
According to a Aug. 3, 2021 press release, WuXi STA—a subsidiary of WuXi AppTec—has finalized its acquisition of Bristol Myers Squibb’s (BMS’) drug product manufacturing facility based in Couvet, Switzerland.
Plans for the acquisition were announced earlier in 2021, and with the successful completion, the newly acquired site is the first in Europe for WuXi STA. The Swiss facility expands WuXi STA’s capacity on a global scale and will afford the company greater access to the European market.
“We are delighted to have added the Couvet site to our global supply network and are excited to welcome its highly skilled team to the WuXi STA family,” said Minzhang Chen, Co-CEO of WuXi AppTec, in the press release. “Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.”
Source: WuXi STA